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Co ro n a ry art e ry disease is the leadingcause of death in diabetic patients(1–3). The Framingham Study showed
an increased incidence of myocardial infarc-
tion, angina, and sudden death in diabetic
patients, particularly in women, and the risk
was independent of the usual risk factors for
c o ro n a ry art e ry disease (3). There f o re, non-
invasive diagnosis of coro n a ry art e ry dis-
ease in diabetic patients is important for
planning a management strategy and for the
selection of patients for coro n a ry angiogra-
phy and possible revascularization. Exerc i s e
s t ress testing is the most common stre s s
modality used for the noninvasive evalua-
tion of coro n a ry art e ry disease. However,
e x e rcise tolerance in diabetic patients may be
i m p a i red, particularly because of the higher
p revalence of peripheral vascular disease.
D o b u t a m i n e - a t ropine stress echocard i o g r a-
phy (DSE) is an accurate and safe altern a t i v e
method that is increasingly used for evalu a-
tion of coro n a ry art e ry disease in patients
unable to perf o rm an adequate exercise test
(4–7). The potential advantages of this tech-
nique in diabetic patients are the ability to
d e fine the early onset of myocard i a l
ischemia in absence of symptoms due to
autonomic neuropathy (8) and the ability to
localize and quantify the amount of
m y o c a rdial ischemia and the extent of coro-
n a ry art e ry disease. Despite the established
s a f e t y, feasibility, and accuracy of DSE for
the diagnosis of coro n a ry art e ry disease
(9–13), these results have not been con-
firmed in diabetic patients. The presence of
diabetic neuropathy can potentially alter
the chro n o t ropic and the inotropic re s p o n s e
to dobutamine, and thereby reduce the abil-
ity of the test to induce myocardial ischemia
or impair the compensatory mechanisms in
response to dobutamine-induced hypoten-
sion, leading to a reduced feasibility of the
test (8,14). Diabetic patients with clinical or
subclinical autonomic neuropathy are at
F rom the Thoraxcenter, University Hospital Rotterdam-Dijkzigt, Erasmus University, Rotterdam, the Netherlands.
A d d ress correspondence to Abdou Elhendy, MD, PhD, Thoraxcenter, Ba 300, Dr Molewaterplein 40, 3015
GD Rotterdam, the Netherlands.
Received for publication 15 September 1997 and accepted in revised form 15 July 1998.
A b b re v i a t i o n s : DSE, dobutamine-atropine stress echocardiography; OR, odds ratio.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion
factors for many substances.
Safety and Feasibility of 
D o b u t a m i n e - A t ropine Stre s s
E c h o c a rdiography for the Diagnosis of
C o ro n a ry Art e ry Disease in Diabetic
Patients Unable to P erfo rm an Exerc i s e
S t ress Te s t
O R I G I N A L  A R T I C L E
O B J E C T I V E — Dobutamine stress testing is increasingly used for the diagnosis and func-
tional evaluation of coro n a ry art e ry disease. However, little is known about the safety and fea-
sibility of this stress modality in diabetic patients.
RESEARCH DESIGN AND METHODS — We studied the impact of diabetes on hemo-
dynamic pro file and on the safety and feasibility of dobutamine (up to 40 µg k g 1 m i n 1) and
a t ropine (up to 1 mg) stress echocardiography for the diagnosis of coro n a ry art e ry disease in
1,446 consecutive patients (aged 60 ± 12 years, 962 men) with limited exercise capacity and sus-
pected myocardial ischemia. Of these, 184 patients were known to have IDDM or NIDDM. The
test was considered feasible when 85% of the maximal heart rate and/or an ischemic end point
(new or worsened wall motion abnormalities, ST segment depression, or angina) was achieved.
R E S U LT S — No myocardial infarction or death occurred during the test. There was no
s i g n i ficant diff e rence between diabetic and nondiabetic patients with re g a rd to heart rate
i n c rease during dobutamine stress echocardiography (58 ± 25 vs. 61 ± 24 beats/min), peak rate
p re s s u re product (18,400 ± 3,135 vs. 18,048 ± 4454), or the prevalence of hypotension (sys-
tolic blood pre s s u re drop of 40 mmHg) (7 vs. 5%), ventricular tachycardia (5.4 vs. 4.5%), and
supraventricular tachycardia (3 vs. 4%) during the test. Dobutamine stress echocard i o g r a p h y
was feasible in 92% of the diabetic patients and in 90% of the nondiabetic patients. Coro n a ry
angiography was perf o rmed in 55 diabetic and 240 nondiabetic patients. Sensitivity, specific i t y,
and accuracy of dobutamine stress echocardiography for the diagnosis of coro n a ry art e ry dis-
ease in diabetic patients were 81, 85, and 82%. Those in nondiabetic patients were 74, 87, and
77%, respectively (NS).
C O N C L U S I O N S — Dobutamine stress echocardiography is a feasible method for the diag-
nosis of coro n a ry art e ry disease in patients with limited exercise capacity with a comparable
s a f e t y, feasibility, and accuracy in diabetic and nondiabetic patients.
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higher risk of ventricular arrhythmias and
sudden death (15). There f o re, the safety of
administration of a high dose of an arrh y t h-
mogenic drug like dobutamine should be
evaluated, particularly knowing that a larg e
number of patients subjected to this test
have left-ventricular dysfunction that may
p rovide a substrate for arrhythmias (16).
We have recently shown that hypert e n s i v e
patients are more likely to develop dobuta-
mine-induced hypotension (13), and there-
f o re, the propensity to develop hypotension
in diabetic patients may also be incre a s e d
because of the higher prevalence of hyper-
tension in diabetic patients. Another con-
founding characteristic of diabetic patients
is the occurrence of left-ventricular dys-
function in the absence of significant coro-
n a ry art e ry disease (17), which may
complicate echocardiographic interpre t a-
tion of wall motion abnormalities during
the test. The aim of this study is to evaluate
the safety, feasibility, and hemodynamic
response to dobutamine-atropine stress test-
ing in diabetic patients with suspected
m y o c a rdial ischemia who are unable to per-
f o rm exercise stress testing.
RESEARCH DESIGN AND
M E T H O D S
Patient population
The study population comprised 1,446 con-
secutive patients with limited exercise capac-
ity who had been re f e rred to our imaging
l a b o r a t o ry for evaluation of myocard i a l
ischemia by DSE. Of these patients, 184
had an established diagnosis of diabetes
a c c o rding to World Health Organization cri-
teria (18) (group 1). There were 40 patients
with IDDM and 144 patients with NIDDM.
G roup 2 comprised 1,262 nondiabetic
patients. Contraindications for DSE were
s e v e re heart failure, significant valvular heart
disease, severe hypertension (blood pre s-
s u re 180/110), hypotension (blood pre s-
s u re 90/60), and unstable chest pain.
Mean age was 60 ± 12 years (962 men). All
patients gave a verbal informed consent to
u n d e rgo the study. The Hospital’s ethical
committee approved the use of DSE for eval-
uation of patients with known or suspected
c o ro n a ry art e ry disease.
Dobutamine stress test
Dobutamine was infused through an antecu-
bital vein starting at a dose of 5 µg k g 1
m i n 1 followed by 10 µg k g 1 m i n 1 ( 3 -
min stages), increasing by 10 µg k g 1
m i n 1 e v e ry 3 min to a maximum of 40 µg 
k g 1 m i n 1. Atropine (up to 1 mg) was
given to patients not achieving 85% of age-
p redicted maximal heart rate, and dobuta-
mine infusion was continued (19). The
e l e c t ro c a rdiogram was monitored thro u g h-
out dobutamine infusion and re c o rded each
minute. Cuff blood pre s s u re was measure d
at rest, every 3 min during stress, and at
maximal stress. The test was interrupted if
s e v e re chest pain, ST-segment depre s s i o n
2 mm, significant ventricular or supra-
ventricular arrhythmia, hypertension (blood
p re s s u re 240/120), systolic blood pre s-
s u re fall 40 mmHg, or any intolerable side
e ffect re g a rded as being due to dobutamine
o c c u rred during the test. Metoprolol (1–5
mg) was available and was used intra-
venously to reverse the effects of dobuta-
mine if they did not re v e rt quickly. The test
was considered feasible if the patient could
achieve 85% of the maximal heart rate pre-
dicted for age and/or when an ischemic end
point (angina, ST-segment depression, new
or worsened wall motion abnormalities) was
re a c h e d .
Stress echocardiography
E c h o c a rdiographic images were acquired at
rest and during stress and re c o v e ry. The
e c h o c a rdiograms were re c o rded on video
tapes and were also digitized on optical
disk and displayed side-by-side in quad-
s c reen format (Vingmed-CFM 800;
Vingmed Sound A/S, Horten, Norway) to
facilitate the comparison of rest and stre s s
images. The left ventricular wall was
divided into 16 segments and scored using
a four-point scale, where 1 = normal, 2 =
hypokinesis, 3 = akinesis, and 4 = dyski-
nesis. Wall motion score index was derived
by dividing the sum of individual scores for
the 16 segments by 16 (19). The interpre-
tation of images was perf o rmed by two
experienced observers without knowledge
of the patients’ clinical data. In case of dis-
a g reement, a majority decision was
achieved by a third observ e r. In our labo-
r a t o ry, the inter- and intraobserver agre e-
ments for DSE assessment are 92 and 94%,
respectively (20). Ischemia was defined as
new or worsening wall motion abnorm a l i-
ties. As we have previously concluded (21),
ischemia was not considered when aki-
netic segments at rest became dyskinetic
during stress without improvement at low-
dose dobutamine (5–10 µg k g 1 m i n 1) .
Coronary angiography
C o ro n a ry angiography was perf o rm e d
within 3 months from DSE in 295 patients.
Lesions were quantified as pre v i o u s l y
described (22). Significant coro n a ry art e ry
disease was defined as a diameter stenosis
50% in 1 major epicardial art e r i e s .
C o ro n a ry arteries were assigned to myocar-
dial segments as previously described (7).
The peri-infarction zone was defined as
m y o c a rdial segments in the distribution of
i n f a rc t - related art e ry (6).
Statistical analysis
Unless specified, data are presented as
mean values ± SD. The 2 test was used to
c o m p a re diff e rences between pro p o rt i o n s .
The Student’s t test was used for analysis of
continuous data. Stepwise logistic re g re s-
sion models were fitted to identify inde-
pendent predictors of hypotension. The
d i ff e rence in risk was expressed as an odds
ratio (OR) with the corresponding 95% CI.
D i ff e rences were considered significant if
the null hypothesis could be rejected at the
0.05 probability level. Sensitivity, speci-
fic i t y, and accuracy of DSE for the diagno-
sis of significant coro n a ry art e ry disease
w e re derived according to standard defin i-
tions and were presented with the corre-
sponding 95% CI.
R E S U LT S
Clinical characteristics
Patient characteristics, medications, and
indications of stress testing in both gro u p s
a re presented in Table 1. Patients of group 1
had a higher prevalence of a history of
h y p e rtension, myocardial infarction, and
congestive heart failure and were re c e i v i n g
d i u retics and angiotensin-convert i n g
enzyme inhibitors more commonly than
patients of group 2. Among the 144 patients
with NIDDM, 24 (17%) were not re c e i v i n g
antidiabetic medication, 80 (56%) were
receiving oral antidiabetic drugs, and 40
(28%) were receiving insulin (in 32 patients
as monotherapy and in 8 patients com-
bined with oral antidiabetic dru g s ) .
Symptoms and hemodynamic
response
T h e re was no death or myocardial infarc t i o n
during or shortly (24 h) after the test. Sys-
tolic blood pre s s u re and heart rate incre a s e d
s i g n i ficantly from rest to peak stress (133 ±
25 [range 90–180] vs. 135 ± 30 [60–280]
mmHg, P 0.00005, and 73 ± 14
[41–130] vs. 133 ± 16 [64–212] beats/min,
P 0.00001), whereas diastolic blood pre s-
s u re decreased significantly (76 ± 13
[45–110] vs. 71 ± 16 [35–130] mmHg, P
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0.00005). Atropine was administered in 649
patients (45%), and the mean dose was sim-
ilar in both groups (0.60 ± 0.29 vs. 0.60 ±
0.28 mg). Atropine induced a signific a n t
comparable increase of heart rate in both
g roups (Table 2). Heart rate, systolic and
diastolic blood pre s s u res, and rate pre s s u re
p roduct were higher in group 1 at rest and
similar for both groups at peak stress. The
p revalence of symptoms and arrh y t h m i a s
was similar in both groups (Table 3). There
was no significant diff e rence between the
two groups with re g a rd to percentage of
patients reaching the target heart rate or the
p revalence of various types of arrh y t h m i a s
( Table 3). Ventricular tachycardia was ter-
minated in all cases spontaneously by stop-
ping dobutamine infusion or administration
of metoprolol. Systolic blood pre s s u re dro p s
of 40 mmHg occurred in 71 patients (5%)
during stress. Multivariate analysis identifie d
baseline systolic blood pre s s u re 1 4 0
mmHg (OR 7.2, 95% CI 3.5–16), older age
(OR 1.03, 95% CI 1.02–1.09), and medica-
tion with calcium channel blockers (OR 1.8,
95% CI 1.2–3.4) as independent pre d i c t o r s
of hypotension. Hypotension was the re a s o n
for test termination in only 30 of the 71
patients who developed hypotension. Rea-
sons for termination of the test are shown in
Table 4. The test was considered feasible
(achievement of 85% of maximal heart rate
and/or an ischemic end point) in 169
patients in group 1 (92%) and in 1,142
patients in group 2 (90%) (P = 0.8).
Stress echocardiography
Wall motion abnormalities were present at
rest in 125 patients in group 1 (68%) and in
724 patients in group 2 (57%) (P 0 . 0 1 ) .
Ischemia was detected in 63 patients in
g roup 1 (34%) and in 426 patients in gro u p
2 (34%), whereas 45 patients in group 1
(24%) and 421 patients in group 2 (33%)
had normal wall motion at rest and during
s t ress (P 0.05). Wall motion score index
i n c reased from rest to stress in group 1
(1.49 ± 0.49 vs. 1.53 ± 0.25, P 0 . 0 0 1 )
and in group 2 (1.37 ± 0.46 vs. 1.41 ± 0.51,
P 0.0001). Wall motion score index was
higher in group 1 than in group 2 at rest (P
0.005) and at stress (P 0 . 0 1 ) .
Accuracy of dobutamine stress
echocardiography for the diagnosis
of coronary artery disease
C o ro n a ry angiography was perf o rmed in
295 patients within 3 months of DSE (55
patients in group 1 and 240 patients in
g roup 2). Significant coro n a ry art e ry dis-
ease was detected in 228 patients (42
patients in group 1 and 186 patients in
g roup 2), while 67 patients (13 patients in
g roup 1 and 54 patients in group 2) had a
n o rmal coro n a ry angiogram or nonsignifi-
cant lesions. Tables 5 and 6 demonstrate
the accuracy of DSE in both groups for the
diagnosis of significant coro n a ry art e ry dis-
ease on the basis of ischemia in patients
with and without previous myocard i a l
i n f a rction. Sensitivity, specific i t y, and accu-
racy were fairly comparable in both gro u p s .
Table 1—Clinical features of diabetic (group 1) and nondiabetic (group 2) patients underg o i n g
D S E
Group 1 Group 2 P value
n 184 1,262 —
Clinical features
Age (years) 60 ± 10 60 ± 12 1
Males 118 (64) 844 (67) 0.5
Previous myocardial infarction 110 (60) 641 (49) 0.01
History of heart failure 41 (22) 183 (15) 0.01
History of hypertension 89 (48) 467 (37) 0.005
Medications
-blockers 58 (32) 444 (35) 0.3
Calcium channel blockers 74 (40) 445 (35) 0.2
Nitrates 76 (41) 458 (36) 0.2
ACE inhibitors 84 (46) 408 (32) 0.0005
Diuretics 60 (33) 280 (22) 0.005
Indications for stress testing
Typical chest pain 60 (33) 401 (32) 0.8
Atypical chest pain 46 (25) 367 (29) 0.3
Exertional dyspnea or fatigue 17 (9) 125 (10) 0.8
Assessment after myocardial infarction 61 (33) 369 (29) 0.3
or revascularization
Data are means ± SD or n (%). 
Table 2—Hemodynamic data of diabetic (group 1) and nondiabetic (group 2) patients underg o i n g
D S E
Group 1 Group 2 P value
n 184 1,262 —
Hemodynamic and stress test variables
H e a rt rate at rest (beats/min) 76 ± 14 72 ± 14 0 . 0 0 0 1
H e a rt rate at peak stress (beats/min) 134 ± 17 133 ± 16 0 . 3
Systolic blood pre s s u re at rest (mmHg) 137 ± 26 132 ± 22 0 . 0 1
Systolic blood pre s s u re at peak stress (mmHg) 137 ± 30 135 ± 29 0 . 6
Diastolic blood pre s s u re at rest (mmHg) 77 ± 13 75 ± 13 0 . 0 6
Diastolic blood pre s s u re at peak stress (mmHg) 70 ± 15 71 ± 16 0 . 4
Rate pre s s u re product at re s t 10,507 ± 3,135 9,521 ± 2,412 0 . 0 0 0 0 1
Rate pre s s u re product at peak stre s s 18,400 ± 3,135 18,048 ± 4,454 0 . 3
H e a rt rate before atropine* (beats/min) 112 ± 23 111 ± 23 0 . 5
H e a rt rate after atropine* (beats/min) 136 ± 19 134 ± 18 0 . 3
Systolic blood pre s s u re before atropine* (mmHg) 131 ± 28 131 ± 25 1
Systolic blood pre s s u re after atropine* (mmHg) 134 ± 25 131 ± 28 0 . 3
Systolic blood pre s s u re drop 20 mmHg 38 (21) 225 (18) 0 . 4
Systolic blood pre s s u re drop 40 mmHg 12 (7) 59 (5) 0 . 3
Maximal dobutamine dose (µg k g 1 m i n 1) 36.5 ± 7.2 37 ± 6.4 0 . 4
A t ropine given 87 (47) 562 (45) 0 . 5
S T-segment depre s s i o n 36 (20) 172 (14) 0 . 0 5
Data are means ± SD or n (%). *Data are taken only from patients who received atropine.
C O N C L U S I O N S — To our knowl-
edge, this is the first study to evaluate the
impact of diabetes on the safety, feasibility,
and diagnostic accuracy of DSE in a larg e
series of patients. Our study demonstrates
that DSE is a feasible and safe method for
evaluation of coro n a ry art e ry disease in dia-
betic patients with suspected myocard i a l
ischemia and limited exercise capacity. No
m y o c a rdial infarction or death occurre d
during the test. Despite the fact that dia-
betic patients had more severe left-ventric-
ular dysfunction at rest, the feasibility and
safety pro file were similar in diabetic and
nondiabetic patients. Ventricular tachycar-
dia was terminated in all cases sponta-
neously by stopping dobutamine infusion
or administration of metoprolol. Minor side
e ffects, including chills, dizziness, flu s h-
ing, headache, nausea, and anxiety, were
common and occurred in 18% of the entire
population. However, these symptoms
w e re usually well tolerated and were the
reason for termination of the test in a
minority of patients (0.07%). The pre v a-
lence of these side effects was similar in dia-
betic and nondiabetic patients.
Hemodynamic response of diabetic
patients to dobutamine
H e a rt rate increased significantly and
equally in patients with and without dia-
betes, and there was no significant diff e re n c e
between the two groups with re g a rd to age,
sex, or the maximal dobutamine dose. This
implies that the chro n o t ropic response to
high-dose dobutamine is not impaired in
diabetic patients. Borow et al. (23) have pre-
viously re p o rted that in norm o t e n s i v e
young adults with diabetes and no evidence
of coro n a ry art e ry disease, the contractile
response to low-dose dobutamine infusion
(5 µg k g 1 m i n 1) was similar to that of
n o rmal subjects despite the occurrence of
ejection fraction drop during exercise in
45% of diabetic patients. Despite the
re p o rted parasympathetic dysfunction in
diabetic patients (16), atropine induced a
similar increase of heart rate in diabetic and
nondiabetic patients in our study, denoting
the feasibility of the administration of this
parasympatholytic agent in achieving a
s i g n i ficant increase of heart rate in diabetic
patients with inadequate chro n o t ro p i c
response to high-dose dobutamine. There
was a modest but significant increase of sys-
tolic blood pre s s u re in nondiabetic patients
f rom rest to peak stress, whereas this failed
to increase in diabetic patients. This may be
explained by the higher baseline systolic
blood pre s s u re and the higher frequency of
medication with angiotensin-convert i n g
enzyme inhibitors in diabetic patients. Both
factors have been implicated in impairm e n t
of blood pre s s u re response to dobutamine
(13,24). Peak systolic blood pre s s u re and
rate pre s s u re product were similar in
patients with and without diabetes, denot-
ing the achievement of a similar hemody-
namic stress re q u i red to provoke myocard i a l
ischemia. The prevalence of symptomatic
and asymptomatic hypotension was similar
in diabetic and nondiabetic patients. Inde-
pendent predictors of hypotension were
medication with calcium antagonists, base-
line systolic blood pre s s u re 140 mmHg,
and older age, which are in accordance with
p revious studies (13).
Comparison with previous studies
Bates et al. (25) studied 53 patients with
IDDM by DSE before kidney and/or pan-
c reatic transplantation. During a follow up
period of 418 ± 269 days, cardiac event
rates were 54% among patients with abnor-
mal DSE and 6% among those with norm a l
DSE by re t rospective analysis. The dobuta-
mine stress test was terminated pre m a t u re l y
because of hypotension in one patient and
nausea in another. The incidence of arrh y t h-
mias during the test was not re p o rted. In our
s t u d y, the prevalence of diff e rent types of
a rrhythmias during dobutamine stress test-
ing was similar in diabetic and nondiabetic
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Table 3—Symptoms and arrhythmias in diabetic (group 1) and nondiabetic (group 2) patients
during dobutamine-atropine stress echocardiography
Group 1 Group 2 P value
n 184 1,262 —
Symptoms/arrhythmias
Nausea 7 (4) 58 (5) 0.6
Flushing 0 (0) 11 (0.9) 0.2
Dizziness 5 (3) 36 (3) 0.9
Anxiety 3 (2) 27 (2) 0.7
Chills 7 (4) 48 (4) 1
Headache 4 (2) 57 (5) 0.1
Symptomatic hypotension 1 (0.5) 17 (1) 0.4
Typical angina 48 (26) 307 (24) 0.6
Premature atrial contractions 13 (7) 90 (7) 0.9
Premature ventricular contractions 63 (34) 397 (31) 0.4
Supraventricular tachycardia 5 (3) 51 (4) 0.4
Atrial fibrillation 2 (1) 17 (1) 0.8
Ventricular tachycardia 10 beats 8 (4) 48 (4) 0.7
Ventricular tachycardia 10 beats 2 (1) 9 (0.07) 0.6
Data are n (%).
Table 4—Reasons for termination of dobutamine stress testing in diabetic (group 1) and
nondiabetic (group 2) patients
Group 1 Group 2 P value
n 184 1,262 —
Reasons for test termination
85% of maximal heart rate 148 (80) 1,028 (81) 0.7
Maximal dose 11 (6) 99 (8) 0.4
Angina 14 (7) 59 (5) 0.09
ST changes 1 (0.5) 15 (1) 0.4
Arrhythmias 5 (3) 20 (2) 0.3
Hypertension 1(0.5) 1 (0.01) 0.1
Hypotension 3 (1.7) 27 (2.1) 0.7
Dyspnea 0 (0) 3 (0.2) 0.5
Chills, flushing, anxiety, dizziness 1 (0.05) 10 (0.07) 0.7
Data are n (%).
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patients. The overall prevalence of supraven-
tricular tachycardia (including atrial fib r i l l a-
tion) (4.8%) and ventricular tachycard i a
(4.8%) in our study is consistent with that
re p o rted by Mertes et al. (9) (4.1% and
4.2% respectively). Arrhythmias were the
reason for termination of the test in 2% of
patients in our study, which is comparable to
the findings of Mertes et al. (2.1%). There
was no diff e rence between diabetic and non-
diabetic patients re g a rding the feasibility of
dobutamine stress testing. Overall feasibility
(91%) is comparable to that re p o rted by
P o l d e rmans et al. (11) (98%), Cornel et al.
(10) (97%), and Picano et al. (12) (88%).
Accuracy of dobutamine stress
echocardiography in diabetic and
nondiabetic patients
To our knowledge, this is the first study that
c o m p a res the diagnostic accuracy of DSE in
diabetic and nondiabetic patients. Sensitiv-
i t y, specific i t y, and accuracy were fairly com-
parable in both groups for the overall
diagnosis of coro n a ry art e ry disease, single-
vessel disease, and multivessel disease, iden-
t i fication of multivessel disease on the basis
of inducible ischemia in 1 vascular terr i-
t o ry, and in the diagnosis of infarc t - re l a t e d
and remote coro n a ry art e ry stenosis. There-
f o re, the diagnostic accuracy of DSE was not
limited in diabetic patients, despite the
m o re severe baseline left-ventricular dys-
function. In the study by Bates et al. (25), 17
diabetic patients underwent coro n a ry
a n g i o g r a p h y. DSE had a sensitivity of 90%
(9 of 10 patients) and a specificity of 86% (6
of 7 patients). However, the number of
patients in that study was small, and the
c o ro n a ry angiogram was perf o rmed late
after DSE in some patients (up to 557 days).
Limitations of the study
Diabetic and nondiabetic patients were not
comparable with re g a rds to clinical charac-
teristics (hypertension, medications, and
Table 5—Accuracy of ischemic pattern at dobutamine stress echocardiography for the diagnosis of significant coron a y art e ry stenosis in diabetic
( g roup 1) and nondiabetic (group 2) patients without previous myocardial infarc t i o n
Number of Number of
Diagnostic parameters Group 1 patients Group 2 patients P value
Overall diagnosis (all patients)
Sensitivity 77 (58–95) 10/13 73 (61–85) 24/33 0.8
Specificity 86 (70–101) 6/7 86 (77–95) 19/22 1
Accuracy 80 (62–98) 16/20 78 (67–89) 43/55 0.9
Sensitivity in patients with single-vessel disease 67 (41–92) 4/6 67 (52–81) 12/18 1
Sensitivity in patients with multivessel disease 86 (67–104) 6/7 80 (67–93) 12/15 0.8
Diagnosis of multivessel disease by multivessel ischemic pattern
Sensitivity 57 (35–79) 4/7 53 (40–67) 8/15 0.9
Specificity 85 (69–100) 11/13 90 (82–98) 36/40 0.6
Accuracy 75 (56–94) 15/20 80 (69–91) 44/55 0.6
Data are % (95% CI) or n.
Table 6—Accuracy of ischemic pattern at dobutamine stress echocardiography for the diagnosis of significant coron a y art e ry stenosis in diabetic
(group 1) and nondiabetic (group 2) patients with previous myocardial infarction
Number of Number of
Diagnostic parameters Group 1 patients Group 2 patients P value
Overall diagnosis (all patients)
Sensitivity 83 (70–95) 24/29 74 (67–80) 113/153 0.3
Specificity 83 (71–96) 5/6 88 (83–92) 28/32 0.8
Accuracy 83 (70–95) 29/35 76 (70–83) 141/185 0.4
Sensitivity in patients with single-vessel disease 60 (31–89) 3/5 61 (50–71) 34/56 1
Sensitivity in patients with multivessel disease 88 (76–99) 21/24 81 (75–88) 79/97 0.5
Diagnosis of multivessel disease by multivessel ischemic pattern
Sensitivity 50 (39–61) 12/24 49 (42–57) 48/97 1
Specificity 82 (69–95) 9/11 91 (87–95) 80/88 0.3
Accuracy 60 (44–76) 21/35 69 (62–76) 128/185 0.3
Infarct-related artery
Sensitivity 71 (56–86) 22/31 61 (54–68) 93/152 0.3
Specificity 75 (61–89) 3/4 85 (80–90) 28/33 0.6
Accuracy 71 (56–86) 25/35 65 (58–72) 121/185 0.5
Remote coronary artery
Sensitivity 72 (57–87) 18/25 67 (60–74) 70/104 0.7
Specificity 90(80–100) 9/10 89 (84–93) 72/81 0.9
Accuracy 77 (63–91) 27/35 77 (70–83) 142/185 1
Data are % (95% CI) or n.
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baseline left-ventricular function). How-
e v e r, the safety pro file was similar in dia-
betic and nondiabetic patients despite the
m o re severe left ventricular dysfunction
and the higher prevalence of hypert e n s i o n
in diabetic patients. We did not study the
autonomic function in diabetic patients,
and there f o re, we were not able to assess
the correlation between the autonomic
function and safety of the test. Coro n a ry
angiography was perf o rmed only in 295
patients (20%). However, this is one of the
l a rgest studies correlating the findings at
DSE with coro n a ry angiography. Finally,
the results of the test were available for the
t reating physicians with possible re f e rr a l
bias for coro n a ry angiography, a factor that
may reduce the specificity of the test by
re f e rring more patients with a positive
rather than a negative test for angiography.
H o w e v e r, specificity in nondiabetic patients
is unlikely to be underestimated compare d
with that in diabetic patients because the
latter have an established risk factor for
c o ro n a ry art e ry disease and a possibly
higher rate of re f e rral of patients with a pos-
itive test for coro n a ry angiography.
Clinical implications and conclusions
It is concluded that DSE is a safe and feasi-
ble method for evaluation of coro n a ry
a rt e ry disease with a comparable chro n o-
t ropic response, safety, feasibility, and diag-
nostic accuracy in diabetic and nondiabetic
p a t i e n t s .
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